- Details
- (Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...
|
- Details
- Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...
|
- Details
- Simpa Salami, MD discusses the role of MRI in risk stratifying patients with prostate cancer. MRI has revolutionized the ability to detect aggressive prostate cancer but it is still possible that patients who have a negative MRI still have aggressive cancer. Up to 10-15% of patients may have aggressive prostate cancer despite negative findings on MRI. Dr. Salami addresses why these patients may ha...
|
- Details
- Michael Morris joins Alicia Morgans for a conversation on the focus of the GU Committee of the Alliance Cooperative Group that is led by Michael Morris. While there is a continued focus on advanced prostate cancer, there is an expected readout on a 12-year study in early disease, the CALGB 90203. CALGB 90203 (Alliance) looked at radical prostatectomy (RP) with or without neoadjuvant chemohormonal...
|
- Details
- Alicia Morgans and Matt Cooperberg discuss the current state of contemporary active surveillance and efforts to standardize strategies nationwide. This conversation also includes discussion on informed decision making and practice patterns of active surveillance and how to tailor based on biology and genetics Biographies: Matthew Cooperberg, MD, MPH, FACS, Associate Professor, Department of Urolog...
|
- Details
- In this interview, Laurence Klotz discusses patients who have yet to be treated but have been diagnosed or in the process of being diagnosed with prostate cancer. Dr. Klotz reviews different case studies including treating a patient with mild elevation of PSA, age-adjusted norms, the use of a risk nomogram in determining significant cancer and deciding on a path of active surveillance. They also d...
|
- Details
- The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an in...
|
- Details
- (Length of Interview: 20 min) John Feller is interviewed by John Fortin on laser focal therapy and focal laser ablation (FLA) therapy for the treatment in prostate cancer. He fields questions including his opinion on the typical candidate, availability and measuring side effects in FLA therapy. In addition, future plans to expand the scope in terms of the number of sites offering this therapy and...
|
- Details
- (Length of Presentation: 8 min) This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer. Biographies: Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands Read the Full Video Transcript {article title="assessment-of-simplified-methods-for-quantification-of-18f-fd...
|
- Details
- Todd Morgan shares the unique program that he and his GU team at the University of Michigan have implemented in an effort to gain a better understanding of the genetics and genomics involved with progression in prostate cancer. Biographies: Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies and an Associate Professor of Urology and has been at...
|
